DL-亮氨酰-DL-苯丙氨酸 | 56217-82-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: DL-亮氨酰-DL-苯丙氨酸
• 英文名称: leucyl-phenylalanine
• 英文别名: 2-[(2-azaniumyl-4-methylpentanoyl)amino]-3-phenylpropanoate
• CAS: 56217-82-4
• 化学式: C₁₅H₂₂N₂O₃
• mdl: MFCD00037258
• 分子量: 278.351
• InChiKey: KFKWRHQBZQICHA-UHFFFAOYSA-N

物化性质

• 沸点：
  501.2±50.0 °C(Predicted)
• 密度：
  1.144±0.06 g/cm3(Predicted)
• 溶解度：
  在1mol/LHCl中几乎透明
• 稳定性/保质期：

  如果按照规格使用和储存，就不会分解，也不存在已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.466
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  DL-亮氨酰-DL-苯丙氨酸 、 2-萘磺酰氯 生成 N-[N-(naphthalene-2-sulfonyl)-leucyl]-phenylalanine
  参考文献：
  名称：

  Otani, Acta Scholae Medicinalis Universitatis in Kioto, 1935, vol. 17, p. 182,194

  摘要：

  DOI：

文献信息

• Novel spergualin-related compounds and process for producing the same
  申请人：MICROBIAL CHEMISTRY RESEARCH FOUNDATION

  公开号：EP0241797A2

  公开（公告）日：1987-10-21

  The present invention relates to novel Spergualin-related compounds represented by the general formula [I] R2 is a residue obtained by removing, from an amino acid or peptide, the hydroxyl group of the carboxyl group and, when R, is a group other than -H, R2 is same as R, , or a pharmacologically acceptable salt thereof. Said compounds or salts thereof have an immune-modulating action. The invention further relates to pharmaceutical formulations having an immuno-modulating activity which contain such Spergualin-related compounds and a process for the manufacture of these compounds and preparations.

  本发明涉及由通式[I]表示的新型 Spergualin 相关化合物 R2 是通过从氨基酸或肽中去除羧基的羟基而得到的残基，当 R 是除-H 以外的基团时，R2 与 R 相同，或其药理上可接受的盐。上述化合物或其盐具有免疫调节作用。 本发明还涉及具有免疫调节活性的药物制剂，其中含有此类与 Spergualin 相关的化合物，以及制造这些化合物和制剂的工艺。
• New spergualin-related compound and pharmaceutical composition
  申请人：ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI

  公开号：EP0309971A2

  公开（公告）日：1989-04-05

  The present invention relates to new spergualin-related compounds having an immunopotentiating effect and represented by the general formula [I]: wherein X represents -(CH2)3-5- or R represents -H or -CH2-OH and R1 and R2 each represents a residue formed by removing a hydroxyl group from the carboxyl group of an amino acid or peptide with the proviso that both of R1 and R2 cannot represent at the same time, and pharmacologically acceptable salts thereof.

  本发明涉及具有免疫增强作用并由通式[I]表示的新的 spergualin 相关化合物： 其中 X 代表-(CH2)3-5-或 R代表-H或- -OH，R1和R2各自代表通过从氨基酸或肽的羧基上除去羟基而形成的残基，但R1和R2不能同时代表 的残基、 及其药理上可接受的盐类。
• Novel spergualin-related compounds and preparation and application of the same
  申请人：NIPPON KAYAKU KABUSHIKI KAISHA

  公开号：EP0347820A1

  公开（公告）日：1989-12-27

  The present invention relates to novel spergualin-related compounds represented by the general formula [I]: wherein X is -(CH₂)₁-₅ OR Y is a hydrogen atom or a residue obtained by removing a hydroxyl group from the carboxyl group of an amino acid or a peptide; m is 0, 1 or 2 and n is 1 or 2, with the proviso that Y is not a hydrogen atom when n is 2 and m is 0. This compounds are stable and exhibit a high immunosuppressive activity.

  本发明涉及由通式[I]表示的新型精蛋白相关化合物： 其中 X 是-(CH₂)₁-₅ OR Y 是氢原子或通过从氨基酸或肽的羧基上去除羟基而得到的残基；m 是 0、1 或 2，n 是 1 或 2，但当 n 是 2 且 m 是 0 时，Y 不是氢原子。 这种化合物性质稳定，具有很高的免疫抑制活性。
• MEDICINAL COMPOSITIONS FOR TREATING IMMUNODEFICIENCY DISEASES
  申请人：Nippon Kayaku Kabushiki Kaisha

  公开号：EP1038533A1

  公开（公告）日：2000-09-27

  Spergualin-related compounds such as 15-deoxyspergualin and pharmacologically acceptable salts thereof possess an activity of suppressing the function of monocyte or macrophage are useful as drugs for the treatment of immunodeficiency accompanied by a reduced CD4+ T cell level as observed in HIV infection.

  具有抑制单核细胞或巨噬细胞功能活性的橙皮苷相关化合物，如 15-脱氧橙皮苷及其药理上可接受的盐类，可用作治疗因 CD4+ T 细胞水平降低而导致的免疫缺陷（如在艾滋病毒感染中观察到的情况）的药物。
• DRY POWDER INHALATION SYSTEM FOR TRANSPULMONARY ADMINISTRATION
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1402913A1

  公开（公告）日：2004-03-31

  The present invention provides a novel dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system of the invention characterized by using a combination of: (1) a vessel housing a freeze-dried composition that contains a single dose of an active ingredient, and has: (i) a non-powder cake-like form, (ii) a disintegration index of 0.015 or more, and (iii) a property of becoming fine particles having a mean particle diameter of 10 microns or less or a fine particle fraction of 10% or more upon receipt of an air impact having an air speed of at least 1 m/sec and an air flow rate of at least 17 ml/sec; and (2) a device comprising means capable of applying said air impact to the freeze-dried composition in said vessel, and means for discharging the powder-form freeze-dried composition that has been made into fine particles.

  本发明提供了一种适用于跨肺给药的新型干粉吸入系统。本发明的干粉吸入系统的特点是采用了以下组合： (1) 一个容纳冷冻干燥组合物的容器，该组合物含有单剂量的活性成分，并具有以下特征 (i) 非粉饼状、 (ii) 崩解指数为 0.015 或以上，以及 (iii) 在受到气速至少为 1 米/秒和气流速率至少为 17 毫升/秒的空气冲击时，成为平均粒径为 10 微米或以下或细颗粒分数为 10%或以上的细颗粒的特性；以及 (iv) 在受到气速至少为 1 米/秒和气流速率至少为 17 毫升/秒的空气冲击时，成为平均粒径为 10 微米或以下或细颗粒分数为 10%或以上的细颗粒的特性。 (2) 一种装置，包括能够对所述容器中的冻干成分施加所述空气冲击的装置，以及将已制成细颗粒的粉末状冻干成分排出的装置。

表征谱图